

**Staphylococcus aureus - NRS272**  
Other designations ( P1V44 )

Demographic Information:			
Country/State:	Belgium	Date of Isolation:	08/01/1999
Patient Age:	18 Year(s)	Gender:	Female
Patient Location:	Inpatient	Patient Service:	Medicine
Culture Source:			
Literature Citation:	Denis O. et al. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemo 50:383-391.		
Donor Reported MIC Results (ug/ml)	Vancomycin = 16		Teicoplanin = N/A
Comment:	N/A		
Repositories:	Glycopeptide Intermediate Staphylococci		

**NARSA Antimicrobial Susceptibility Data for Glycopeptides**

Drug	Broth Microdilution		<sup>a</sup> Conventional Etest 0.5 McFarland Std		<sup>b</sup> Modified Etest 2 McFarland Std		<sup>c</sup> BHI Agar Screen	Disk Diffusion	
	µg/mL MIC <del>pg/ml</del>	CLSI Interprtn	MIC µg/ml	CLSI Interprtn	MIC µg/ml	CLSI Interprtn		Zone diam. (mm)	CLSI Interprtn
<b>Vancomycin:</b>	= 4	S	= 4	S	= 48	R	CG(24)	21	S
<b>Teicoplanin:</b>	= 16	I	= 6	S	> 256	R		19	S

S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	µg/mL MIC <del>(pg/ml)</del>	CLSI Interprtn	PCR	Result
Ciprofloxacin	= 4	R	<i>vanA</i>	NEGATIVE
Clindamycin	= 0.06	S	<i>vanB</i>	NEGATIVE
Daptomycin	= 2	N/A	<i>vanC1</i>	NEGATIVE
Erythromycin	> 8	R	<i>vanC2</i>	NEGATIVE
Gentamicin	> 16	R	<i>vanD</i>	NEGATIVE
Linezolid	= 2	S	<i>vanE</i>	NEGATIVE
Oxacillin	= 4	R	<i>mecA</i>	POSITIVE
Penicillin	= 0.5	R		
Quinupristin/dalfopristin	<= 0.12	S		
Trimeth/sulfa	= 0.5/9.5	S		

Genotype Data	
Genotype	Result
eGenomic <i>spa</i> type	927
eGenomic <i>spa</i> repeats	YHFHFGFMBQBLO

<b>Ridom <i>spa</i> type</b>	t770
<b>SCC<i>mec</i> type</b>	IV
<b>Clonal Complex (CC)</b>	8 (247)
<b>Sequence Type (ST)</b>	247
<a href="#">Genotype Data file</a>	